(Q84356593)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21670972%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

title

Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21670972%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference

ChEBI release 2020-05-28

1 reference

Jean-Philippe Spano

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21670972%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Malcolm J Moore

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21670972%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Yazdi K Pithavala

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21670972%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Alejandro D Ricart

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21670972%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Sinil Kim

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21670972%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Olivier Rixe

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21670972%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

publication date

14 June 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21670972%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

4 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21670972%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21670972%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21670972%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

page(s)

1531-1539

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21670972%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10637-011-9697-2

4 February 2020

exact match

0 references

cites work

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

1 reference

12 December 2020

Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial

1 reference

12 December 2020

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

1 reference

12 December 2020

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

1 reference

12 December 2020

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

1 reference

12 December 2020

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

12 December 2020

Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205

1 reference

12 December 2020

New developments in the treatment of pancreatic cancer. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008.

1 reference

12 December 2020

Investigation of the pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in human plasma by liquid chromatography

1 reference

12 December 2020

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

1 reference

12 December 2020

Cancer statistics, 2010

1 reference

12 December 2020

Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer

1 reference

12 December 2020

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer

1 reference

12 December 2020

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer

1 reference

12 December 2020

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

1 reference

12 December 2020

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

1 reference

12 December 2020

Gemcitabine in patients with solid tumors and renal impairment: a pharmacokinetic phase I study

1 reference

12 December 2020

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

1 reference

12 December 2020

Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.

1 reference

12 December 2020

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

1 reference

12 December 2020

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study

1 reference

12 December 2020

Pathways for aberrant angiogenesis in pancreatic cancer

1 reference

12 December 2020

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study

1 reference

12 December 2020

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

1 reference

12 December 2020

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

1 reference

12 December 2020

Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.

1 reference

12 December 2020

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

12 December 2020

Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray

1 reference

12 December 2020

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

12 December 2020